The goal of the alliance is to offer pharmaceutical companies, who are seeking productivity gains in discovering and developing lead molecules, a seamless end-to-end cloud-based solution using both Quinten’s and Cyclica’s technologies.
With Quinten’s core technology, Q-Finder®, chemists will be able to efficiently optimize a lead compound in terms of pharmacokinetic and on-target parameters. With Cyclica’s Ligand Express™ technology, they will then be able to understand and gain critical insights into the lead compound’s polypharmacology through off-target profiles generated by matching the compound against Cyclica’s proprietary database of all structurally-characterized proteins. This combined platform will provide novel, understandable and immediately actionable insights on the properties of a lead molecule and its opportunity for therapeutic efficacy. It will also flag potential toxicological properties prior to clinical studies, ultimately enhancing productivity in drug development.
Alexandre Templier, Chairman and CEO of Quinten, said: “We are very impressed with Cyclica’s technology, and believe that there is a large opportunity and a need in the market for the combined offering. An integrated solution in the hands of scientists will help guide better and more cost-effective decisions in drug development, and we are excited to present the enhanced value proposition to our existing and future clients.”
“Quinten has deep expertise in data science and information technology, with several successes in the pharmaceutical industry. We believe that by working with Quinten, we will be able to lead the charge in innovation with the goal of effecting broad and sustainable change across the pharmaceutical industry. This alliance is just what the market is asking for, and there is no better partner for us than Quinten”, said Naheed Kurji, President and CEO of Cyclica.